![]() There was no significant difference between the groups for BDI scores. Homocysteine levels of the group recovering from COVID-19 (x − = 19.065 µmol/L) were higher than the control group (x − = 11.313 µmol/L). ![]() Beck Depression Inventory (BDI) and Montreal Cognitive Assessment (MoCA) were performed to collect data. At first, the homocysteine levels of participants were measured. It included 62 people recovering from COVID-19 (at least 3 months after positive RT-PCR) and 64 people without COVID-19 (control group). Moreover, we aimed to investigate the relationship between depression and cognition levels by measuring homocysteine concentrations. In this study, we measured the levels of depression and cognition in people recovering from COVID-19. Authors may use MDPI'sĮnglish editing service prior to publication or during author revisions. Submitted papers should be well formatted and use good English. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Please visit the Instructions for Authors page before submitting a manuscript. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. All manuscripts are thoroughly refereed through a single-blind peer-review process. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. ![]() Research articles, review articles as well as short communications are invited. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. All submissions that pass pre-check are peer-reviewed. ![]() Manuscripts can be submitted until the deadline. Once you are registered, click here to go to the submission form. Manuscripts should be submitted online at by registering and logging in to this website. Advances in diagnosis, definition of pathophysiological models, and treatment strategies will be further investigated. Therefore, the aim of the present Special Issue, published in the Journal of Personalized Medicine, is to provide a comprehensive description of the neurological and psychiatric effects of COVID-19. However, despite the efforts made to define, classify, and treat COVID-19-related neuropsychiatric diseases, their characteristic underlying neurobiology remains largely unknown. A steep surge or worsening of neurologic and psychiatric syndromes has been reported during and after SARS-CoV-2 infection, including confusion, depression, anxiety, post-traumatic stress disorder, dementia, and psychosis. Among all the organs involved, the brain is one of the most severely affected. Now, after two years of the pandemic, there is robust evidence documenting that COVID-19 extends beyond the pulmonary system. Since then, the SARS-CoV-2 infection has spread globally. Towards the end of 2019, a new respiratory syndrome, now known as coronavirus disease 2019 (COVID-19), was reported in Wuhan, China.
0 Comments
Leave a Reply. |